SPS
ALNY icon

Susquehanna Portfolio Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Hold
5,005
– – 0.02% 540
2025
Q4 		$1.99M Hold
5,005
– – 0.03% 501
2025
Q3 		$2.28M Hold
5,005
– – 0.04% 487
2025
Q2 		$1.63M Buy
+5,005
New +$1.38M 0.04% 410

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Portfolio Strategies's ALNY Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 5,005 shares worth $1.66M. The position accounts for 0.02% of the portfolio, ranked #540.

Susquehanna Portfolio Strategies first reported a position in ALNY in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.28M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Susquehanna Portfolio Strategies held 5,005 shares of Alnylam Pharmaceuticals worth $1.66M as of Q1 2026.
  • Susquehanna Portfolio Strategies left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #540 holding.
  • Susquehanna Portfolio Strategies first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's Alnylam Pharmaceuticals position peaked at $2.28M in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.